Submission of Statement of Deviation & Variation for the quarter December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals Ltd (formerly Trimurthi Limited) has submitted a routine SEBI compliance filing confirming no deviation or variation in the use of funds raised through three separate issues during the quarter and prior periods. The company raised Rs. 231.75 lakhs on August 14, 2025, Rs. 249.15 lakhs on October 23, 2025, and Rs. 161.10 lakhs on December 24, 2025 — a combined Rs. 642 lakhs. All three amounts have been fully utilised towards long-term funding requirements, working capital, and general corporate purposes to support the company's future growth plans. The Audit Committee and Board reviewed the statement on February 12, 2026, and raised no comments. No monitoring agency was appointed for these fund raises.
This is a routine regulatory disclosure confirming disciplined and fully compliant use of freshly raised capital, with no misuse or reallocation of funds. Shareholders can take comfort that management is deploying capital as promised, but this filing is unlikely to have any material impact on the stock price as it carries no new business information.